Behshad Sheldon (born 1963) is Board Member since 2018. She is also Member of the Remuneration Committee.
Her work experience includes the position as President & CEO of Braeburn Pharmaceuticals until 2017. She has also extensive global and US experience from various senior positions in international pharmaceutical companies, including Smithkline Beecham, Bristol-Myers Squibb and Otsuka Pharmaceuticals.
Beshad holds a B.Sc. in Neuroscience from University of Rochester.
Other current appointments: Chairman of the Board of FORCE (Female Opioid Research and Clinical Experts) in Princeton, New Jersey, Board Member, Maxona Pharmaceuticals, Philadelphia, Pennsylvania; EVP & Managing Director, Biotech Value Advisors.
Holdings: 1,000 shares
Independent in relation to the company and its management and the company’s major shareholders.